Oruka Therapeutics

Recent news

• Rating change
  Stifel Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Maintains Target Price $150
  Market Newswire · 2026/6/29
• UBS Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Maintains Target Price $130
  Market Newswire · 2026/9/2
• Rating change
  LifeSci Capital Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Maintains Target Price $125
  Market Newswire · 2026/8/1
• Rating change
  Analysts Have Conflicting Sentiments on These Healthcare Companies: Fractyl Health, Inc. (GUTS) and Oruka Therapeutics (ORKA)
  TipRanks · 2026/9/2
• Rating change
  Analysts Offer Insights on Healthcare Companies: Oruka Therapeutics (ORKA), Alto Neuroscience, Inc. (ANRO) and Astrana Health (ASTH)
  TipRanks · 2026/7/14
• Company notice
  Kaishan Co., Ltd.: The holding company KS Orka Renewables Pte Ltd and PT Optima Nusantara Energi's announcement on joint development of the Simbolon-Samosir geothermal project
  SZSI · 2018/3/19
• Company notice
  Kaishan Co., Ltd.: Announcement on the signing of a letter of intent for a joint venture between its wholly-owned subsidiary KS ORKA and a Hungarian partner
  SZSI · 2025/11/27
• Rating change
  UBS Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Maintains Target Price $100
  Market Newswire · 2026/6/2
• Wedbush Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Maintains Target Price $165
  Market Newswire · 2026/9/24
• Barclays Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Maintains Target Price $160
  Market Newswire · 2026/9/21
• Rating change
  A Quick Look at Today's Ratings for Oruka Therapeutics(ORKA.US), With a Forecast Between $151 to $200
  Market Newswire · 2026/8/11
• A Quick Look at Today's Ratings for Oruka Therapeutics(ORKA.US), With a Forecast Between $120 to $175
  Market Newswire · 2026/9/24
• Rating change
  LifeSci Capital Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Maintains Target Price $175
  Market Newswire · 2026/9/9
• Rating change
  UBS Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Raises Target Price to $130
  Market Newswire · 2026/7/1
• Rating change
  Piper Sandler Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Maintains Target Price $180
  Market Newswire · 2026/8/17
• Company notice
  Kaishan Co., Ltd.: Announcement on KS ORKA Hungary\'s acquisition of exclusive geothermal exploration rights in Hungary
  SZSI · 2025/4/10
• Rating change
  H.C. Wainwright Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Maintains Target Price $120
  Market Newswire · 2026/9/3
• Rating change
  A Quick Look at Today's Ratings for Oruka Therapeutics(ORKA.US), With a Forecast Between $133 to $180
  Market Newswire · 2026/8/12
• Rating change
  TD Cowen Maintains Oruka Therapeutics(ORKA.US) With Buy Rating
  Market Newswire · 2026/8/26
• BTIG Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Maintains Target Price $151
  Market Newswire · 2026/10/2

Headlines are aggregated automatically and are not independently verified or edited by our team.